Ascendis Pharma A/S ADR [ASND] stock is trading at $228.65, up 5.53%. It is a good measure of the stock’s recent performance to check whether the stock’s short-term value is rising or falling. The ASND shares have gain 5.21% over the last week, with a monthly amount glided 14.33%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Ascendis Pharma A/S ADR [NASDAQ: ASND] stock has seen the most recent analyst activity on November 18, 2025, when Wolfe Research initiated its Peer Perform rating and assigned the stock a price target of $255. Previously, Raymond James started tracking the stock with Strong Buy rating on October 17, 2025, and set its price target to $271. Morgan Stanley upgraded its rating to an Overweight but stick to its price target of $250 on May 05, 2025. RBC Capital Mkts initiated its recommendation with an Outperform and recommended $205 as its price target on April 16, 2025. UBS started tracking with a Buy rating for this stock on January 07, 2025, and assigned it a price target of $196. In a note dated September 05, 2024, Oppenheimer upgraded an Outperform rating on this stock but restated the target price of $180.
Ascendis Pharma A/S ADR [ASND] stock has fluctuated between $118.03 and $229.94 over the past year. Currently, Wall Street analysts expect the stock to reach $272.5 within the next 12 months. Ascendis Pharma A/S ADR [NASDAQ: ASND] shares were valued at $228.65 at the most recent close of the market. An investor can expect a potential return of 19.18% based on the average ASND price forecast.
Analyzing the ASND fundamentals
Ascendis Pharma A/S ADR [NASDAQ:ASND] reported sales of 720.68M for the trailing twelve months, which represents a growth of 292.94%. Gross Profit Margin for this corporation currently stands at 0.87% with Operating Profit Margin at -0.23%, Pretax Profit Margin comes in at -0.35%, and Net Profit Margin reading is -0.36%. To continue investigating profitability, this company’s Return on Assets is posted at -0.2, Equity is 1.42 and Total Capital is -0.87. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at -4.67.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance.
Ratios To Look Out For
For context, Ascendis Pharma A/S ADR’s Current Ratio is 1.03. Further, the Quick Ratio stands at 0.73, while the Cash Ratio is 0.55. Considering the valuation of this stock, the price to sales ratio is 19.39.
Transactions by insiders
Recent insider trading involved MIKKELSEN JAN MOLLER, Officer, that happened on Jan 13 ’26 when 86860.0 shares were purchased. Officer, JENSEN MICHAEL WOLFF completed a deal on Dec 04 ’25 to buy 10000.0 shares. Meanwhile, CEO Jan Moller Mikkelsen bought 100000.0 shares on Dec 02 ’25.
